Forum Health Launches Groundbreaking AI Technology to Detect Signs of Heart Disease at an Earlier Stage

Forum Health Fond du Lac, a Forum Health national integrative and functional medicine network, has launched the Multifunction Cardiogram™ (MCG™) scan for early detection of heart disease and cardiac abnormalities.

Phil Hagerman, Forum Health CEO: “Our vision is to use advanced technologies like AI in everything we do. The MCG™ scan uses AI to identify potential heart issues before they escalate into life-threatening conditions. Fond du Lac is the first clinic in our network to launch this technology with great success and we plan to expand it to other clinics.”

The MCG™ scan is a preventative measure that can be used in youth and general populations that are increasingly at risk of heart-related disease. Unlike traditional methods that rely on the onset of symptoms, the MCG™ scan uses advanced artificial intelligence (AI) technology to identify a wide range of cardiac concerns, including:

-Coronary artery disease
-Myocarditis
-Microvascular disease
-Rhythm disturbances
-Heart stiffening
-Plaque instabilities
-Occlusions with high sensitivity

Dr. Steven Meress, Forum Health Fond du Lac: “The MCG™ scan is a revolutionary cardiac device. In March 2023, we performed the first round of scans; five months later, 12 out of 12 follow-up scans show improvement. This evidence shows how effective early interventions can be when based off the MCG™ scan and the positive impact on cardiac health.”

The Multifunction Cardiogram™ scan is powered by AI-driven technology, which continuously learns and improves with each test conducted. Each scan is compared to a robust database of more than 200,000 patients with established cardiovascular disease and assigned an objective heart dysfunctional burden score. This score ranks the patient’s heart health, empowering physicians to make informed decisions and develop personalized treatment plans.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.